SCHEMBL15415918

SCHEMBL15415918

FC(F)(F)c1cn[c]nc1N1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK3 P52333 2/20 0.41
AR P10275 1/20 0.39
CNR2 P34972 2/20 0.39
ULK1 O75385 1/20 0.38
HPGD P15428 3/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
MEN1 O00255 2/20 0.36
GAA P10253 2/20 0.36
KMT2A Q03164 2/20 0.36
LMNA P02545 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
TLR7 Q9NYK1 1/20 0.35
SCN10A Q9Y5Y9 5/20 0.34
MAPK1 P28482 1/20 0.34
MAPT P10636 2/20 0.33
NPY5R Q15761 1/20 0.33
CASP1 P29466 1/20 0.33
CASP7 P55210 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16792297 0.95 JAK3 (0.37) JAK3ARCNR2ULK1HPGD
SCHEMBL19410877 0.81 HPGD (0.33) JAK3HPGDKDM4EMEN1KMT2A
SCHEMBL19410911 0.81 MEN1 (0.35) JAK3HPGDKDM4EMEN1KMT2A
SCHEMBL16792289 0.77 HPGD (0.37) HPGDKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL15415347 0.77 HPGD (0.39) HPGDKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL8656365 0.77 HPGD (0.39) HPGDKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL15415207 0.76 ALOX5 (0.40) JAK3HPGDKDM4EALDH1A1MEN1
SCHEMBL15415930 0.74 SMN1; SMN2 (0.40) HPGDKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL15415897 0.74 HPGD (0.37) HPGDKDM4EALDH1A1L3MBTL1MEN1
SCHEMBL16795112 0.72 SMN1; SMN2 (0.37) HPGDKDM4EALDH1A1L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10273247-B2 Imidazothiazole derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2019-04-30 US disclosed
US-9988383-B2 Purine derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2018-06-05 US disclosed
US-9714251-B2 Imidazotriazine derivatives as modulators of TNF activity UCB BIOPHARMA SPRL (BE) 2017-07-25 US disclosed
US-20160376290-A1 Imidazothiazole Derivatives as Modulators of TNF Activity UCB BIOPHARMA SPRL (BE) 2016-12-29 US disclosed
US-20160376276-A1 Imidazotriazine Derivatives as Modulators of TNF Activity UCB BIOPHARMA SPRL (BE) 2016-12-29 US disclosed
EP-3080126-A1 PURINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2016-10-19 EP disclosed
EP-3080111-A1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2016-10-19 EP disclosed
EP-3080112-A1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2016-10-19 EP disclosed
EP-3080129-A1 IMIDAZOTRIAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2016-10-19 EP disclosed
EP-3080127-A1 IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2016-10-19 EP disclosed
WO-2015086513-A1 TETRAHYDROBENZIMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
WO-2015086505-A1 PURINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
WO-2015086504-A1 IMIDAZOTHIAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
WO-2015086507-A1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
WO-2015086502-A1 PYRAZOLOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
WO-2015086501-A1 IMIDAZOPYRIDAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
WO-2015086499-A1 IMIDAZOPYRIMIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
WO-2015086503-A1 IMIDAZOTRIAZINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB BIOPHARMA SPRL (BE) 2015-06-18 WO disclosed
EP-2872508-A1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB Biopharma SPRL (BE) 2015-05-20 EP disclosed
WO-2014009295-A1 IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY UCB PHARMA S.A. (BE) 2014-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160376290-A1 Imidazothiazole Derivatives as Modulators of TNF Activity TNF, TNFRSF1A, TNFRSF9 JAK3 323/4885AR 3263/4885CNR2 3458/4885
US-20160376276-A1 Imidazotriazine Derivatives as Modulators of TNF Activity TNF, TNFRSF1A, IL1A JAK3 1013/4885AR 3409/4885CNR2 2264/4885
US-10273247-B2 Imidazothiazole derivatives as modulators of TNF activity TNF, TNFRSF1A, TNFRSF9 JAK3 323/4885AR 3263/4885CNR2 3458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.